EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

Late-Onset Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy

Spät auftretende immunvermittelte unerwünschte Ereignisse nach Therapie mit Immun-Checkpoint-Inhibitoren

Sienna M Durbin, Leyre Zubiri, Katherine Perlman, Chia-Yun Wu, Tristan Lim, Kelley Grealish, Nora Hathaway, Jaclyn LoPiccolo, Mike Wang, Ayo Falade, Gabriel Molina, Ted Victor Jacoby und 3 weitere

JAMA Network Open · 27.03.2025 · 8 (3) · e252668

DOI: 10.1001/jamanetworkopen.2025.2668 ↗

Auf einen Blick

Bei 795 hospitalisierten Patient:innen mit irAEs traten 14,7 % nach 6 bis 12 Monaten und 10,8 % nach mehr als 12 Monaten auf. Späte irAEs waren möglich, teils Jahre nach Therapiebeginn.

Fragestellung

Wie häufig treten spät einsetzende irAEs nach Beginn einer ICI-Therapie auf, und welche Patient:innenfaktoren sind damit assoziiert?

Methode

Retrospektive Beobachtungskohortenstudie in einem akademischen Zentrum; Einschluss von Patient:innen mit ICI-Therapie und Hospitalisierung wegen irAE von Januar 2011 bis Oktober 2022.

Ergebnisse

Unter 795 Patient:innen lag das mediane Intervall bis zur Aufnahme bei 2,7 Monaten (IQR 1,2-6,1). 14,7 % traten nach 6 bis 12 Monaten und 10,8 % nach mehr als 12 Monaten auf; Nieren- und hämatologische irAEs waren am ehesten spät.

Schlussfolgerung der Autor:innen

Die Ergebnisse sprechen dafür, dass späte irAEs möglich sind, auch Jahre nach Beginn der ICI-Therapie. Ärzt:innen sollen unabhängig von der vergangenen Zeit wachsam bleiben.

Kernaussagen

  • 14,7 % der irAE-Hospitalisationen traten nach 6 bis 12 Monaten auf
  • 10,8 % traten nach mehr als 12 Monaten auf
  • Späte irAEs betrafen besonders Niere und hämatologische Organsysteme

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Beobachtungsstudie in der Zeitschrift JAMA Network Open, online erschienen am 27.03.2025. Verfasst von Sienna M Durbin und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology & Oncology, Department of Medicine, Massachusetts General Hospital, Boston. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Drug-Related Side Effects and Adverse Reactions, Neoplasms. Die Arbeit wurde bisher 68-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance The use of immune checkpoint inhibitors (ICIs) is increasing. Little is known about the frequency of late-onset immune-related adverse events (irAEs) and the patient-specific risk factors associated with their development.

Objectives

To assess the incidence of persistent or de novo late-onset irAEs requiring hospitalization and identify patient factors associated with risk of late-onset irAEs. Design, Setting, and Participants This retrospective observational cohort study conducted from January 2011 to October 2022 included patients who received ICIs and were hospitalized with irAEs at an academic medical center. Exclusion criteria included ICI therapy outside of the hospital system and no irAE diagnosis during admission. Data were analyzed from November 15, 2022, to January 8, 2025. Exposure Late-onset irAEs. Main Outcomes and Measures The main study outcomes were (1) incidence of irAE hospitalization at 0 to 6 months (early), more than 6 to 12 months (intermediate), and more than 12 months (late) after ICI initiation and (2) patient factors associated with risk of late-onset irAEs.

Results

Among the 795 patients hospitalized with irAEs, the median age was 67.3 years (IQR, 58.3-74.8 years); 476 (59.9%) were male. Most patients (n = 517 [65.0%]) received anti–programmed death ligand 1 (PD-L1) and anti–programmed cell death 1 monotherapy, with the most common indications being melanoma (n = 335 [42.1%]) and lung cancer (n = 167 [21.0%]). The median time from start of ICI therapy to hospital admission was 2.7 months (IQR, 1.2-6.1 months), with 14.7% of patients (n = 117 of 795) presenting 6 to 12 months after initial ICI exposure and 10.8% of patients (86 of 795) presenting more than 12 months after initial exposure. The irAEs most likely to present late included those involving the kidney (10 of 32 [31.3%]) and hematologic (5 of 23 [21.7%]) organ systems. In univariate analysis, ICI type was significantly associated with the timing of hospital admission for irAEs; of the 517 patients receiving anti–PD-L1–based therapy, 13.5% (n = 70) presented late compared with 5.4% (9 of 167) receiving dual therapy with anti–cytotoxic T-lymphocyte–associated protein 4 ( P < .001). Patients receiving perioperative ICI therapy were significantly more likely to be admitted at the intermediate interval (16 of 68 [23.5%]) compared with those with metastatic disease (87 of 678 [12.8%]) ( P = .03). Timing of irAE was also significantly associated with active ICI exposure; among the patients presenting late, 7.4% (48 of 651) had received ICI therapy within the last 60 days compared with 26.4% (38 of 144) who had not had recent ICI exposure ( P < .001). Conclusions and Relevance The findings of this retrospective observational cohort study suggest that late irAEs are possible, with a subset of patients presenting years after the start of ICI therapy. Clinicians must remain vigilant for irAEs regardless of elapsed time from ICI therapy, especially as patients live longer and ICIs become more widely used. Future investigations are needed to better understand the risk factors for late-onset irAEs and the distinct immunologic pathways that underlie such events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsDrug-Related Side Effects and Adverse ReactionsNeoplasmsHumansMaleFemaleRetrospective StudiesAgedMiddle AgedIncidenceHospitalizationRisk Factors

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Division of Hematology & Oncology, Department of Medicine, Massachusetts General Hospital, Boston.
  • Harvard Medical School, Boston, Massachusetts.
  • Department of Dermatology, Massachusetts General Hospital & Harvard Medical School, Boston.
  • Department of Medicine, University of Chicago, Chicago, Illinois.
  • Far Eastern Memorial Hospital, New Taipei City, Taiwan.
  • Dana Farber Cancer Institute, Boston, Massachusetts.

Zitieren

APA

Durbin, S. M., Zubiri, L., Perlman, K., Wu, C. Y., Lim, T., Grealish, K., Hathaway, N., LoPiccolo, J., Wang, M., Falade, A., Molina, G., Jacoby, T. V., Shah, N., Mooradian, M. J., & Reynolds, K. L. (2025). Late-Onset Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy. JAMA Network Open, 8(3), e252668. https://doi.org/10.1001/jamanetworkopen.2025.2668

Vancouver

Durbin SM, Zubiri L, Perlman K, Wu CY, Lim T, Grealish K, et al. Late-Onset Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy. JAMA Network Open. 2025;8(3):e252668. doi:10.1001/jamanetworkopen.2025.2668

BibTeX
@article{Durbin2025,
  author = {Durbin, Sienna M and Zubiri, Leyre and Perlman, Katherine and Wu, Chia-Yun and Lim, Tristan and Grealish, Kelley and Hathaway, Nora and LoPiccolo, Jaclyn and Wang, Mike and Falade, Ayo and Molina, Gabriel and Jacoby, Ted Victor and Shah, Nishi and Mooradian, Meghan J and Reynolds, Kerry L},
  title = {Late-Onset Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy},
  journal = {JAMA Network Open},
  year = {2025},
  volume = {8},
  number = {3},
  pages = {e252668},
  doi = {10.1001/jamanetworkopen.2025.2668}
}
Kostenlos starten →